Unlearn Appoints AstraZeneca’s Chief Medical Officer Ann E. Taylor, M.D. to Board of Directors

Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to enable smaller, faster clinical trials, today announced the appointment of Ann E. Taylor, M.D. to the company’s Board of Directors. Dr. Taylor currently serves as Chief Medical Officer at AstraZeneca and is a leading expert in clinical development.

“We are honored to welcome Dr. Taylor to the Unlearn team. Her deep expertise in clinical development and leadership in the pharmaceutical industry will be invaluable as we work towards expanding our clinical trial collaborations globally,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. “Unlearn is in an exciting phase of growth and with the support of forward-thinking executives like Dr. Taylor, we are poised to expand the use of our Digital Twins and help accelerate clinical trials and the delivery of new medicines to patients.”

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
White Papers

Incorporating External Control Arms into Clinical Trials

White Papers

Applications of Digital Twins in Clinical Trials for Alzheimer’s Disease


Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.
How Digital Twins make it possible to design and run more efficient clinical trials with well-defined statistical properties.
Synthetic Controls and Digital Twins both increase power, but only Digital Twins are robust to known as well as unknown confounders.